Anna Jansana

Dr. Anna Jansana

International Agency For Research On Cancer, Lyon, Auvergne-Rhône-Alpes, France
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2021 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
AJAnna Jansana
Anna Jansana
BPBeatriz Poblador‐Plou
Beatriz Poblador‐Plou
AGAntonio Gimeno‐Miguel
Antonio Gimeno‐Miguel
MLManuela Lanzuela
Manuela Lanzuela
APAlexandra Prados‐Torres
Alexandra Prados‐Torres
SGSURBCAN Group
SURBCAN Group

22 March 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LDLaia Domingo
Laia Domingo
MCMerce Comas
Merce Comas
AJAnna Jansana
Anna Jansana
JLJavier Louro
Javier Louro
HTHelena Tizón-Marcos
Helena Tizón-Marcos
XCXavier Castells
Xavier Castells
Few studies have assessed the impact of the COVID-19 pandemic on non-COVID diseases and healthcare quality. We aimed to evaluate changes in rates of hospitalisations, complications, in-hospital mortality, and readmissions among patients with non-COVID diseases during a one-year period after the pandemic onset. From March 2018 to February 2021 a retrospective observational study of hospital admissions in a university hospital in Spain was conducted. Non-COVID hospitalisations admitted through the emergency department were compared between the pre-COVID period (n = 28,622) and the COVID period (n = 11,904). We assessed rate ratios (RaR), comparing the weekly number of admissions and risk ratios (RR) to examine rates of complications, in-hospital mortality, readmissions, and severity. Statistical significance was set at p < 0.05. The weekly admission rate dropped by 20.8% during the complete lockdown. We observed significant reductions in admissions related to diseases of the respiratory system and circulatory system. Admissions for endocrine and metabolic diseases increased. The complication rates increased (RR = 1.21, 95% CI: 1.05;1.4), while in-hospital mortality rates held steady during the COVID period (RR = 1.09, 95% CI: 0.98;1.2). Hospital efforts to maintain quality and safety standards despite disruptions translated into a moderate increase in complications but not in in-hospital mortality. Reduced hospitalisations for conditions requiring timely treatment may have significant public health consequences.

17 August 2023 in Birth
Verified
Journal Article
Open access
RPRoser Palau‐Costafreda
Roser Palau‐Costafreda
SGSara García Gumiel
Sara García Gumiel
AVAmaranta Eles Velasco
Amaranta Eles Velasco
AJAnna Jansana
Anna Jansana
LOLluna Orus‐Covisa
Lluna Orus‐Covisa
Ramon EscurietRamon Escuriet
Ramon Escuriet
Background: Midwife‐led units have been shown to be safer and reduce interventions for women at low risk of complications at birth. In 2017, the first alongside birth center was opened in Spain. The aim of this study was to compare outcomes for women with uncomplicated pregnancies giving birth in the Midwife‐led unit (MLU) and in the Obstetric unit (OU) of the same hospital.Methods: Retrospective cohort study comparing birth outcomes between low‐risk women, depending on their planned place of birth. Data were analyzed with an intention‐to‐treat approach for women that gave birth between January 2018 and December 2020.Results: A total of 878 women were included in the study, 255 women chose to give birth in the MLU and 623 in the OU. Findings showed that women in the MLU were more likely to have a vaginal birth (91.4%) than in the OU (83.8%) (aOR 2.98 [95%CI 1.62–5.47]), less likely to have an instrumental delivery, 3.9% versus 11.2% (0.25 [0.11–0.55]), to use epidural analgesia, 19.6% versus 77.9% (0.15 [0.04–0.17]) and to have an episiotomy, 7.4% versus 15.4% (0.27 [0.14–0.53]). There were no differences in rates of postpartum hemorrhage, retained placenta, or adverse neonatal outcomes. Intrapartum and postpartum transfer rates from the MLU to the OU were 21.1% and 2.4%, respectively.Conclusions: The high rate of obstetric interventions in Spain could be reduced by implementing midwife‐led units across the whole system, without an increase in maternal or neonatal complications.

9 September 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
AJAnna Jansana
Anna Jansana
IGIsabel Del-Cura González
Isabel Del-Cura González
APAlexandra Prados-Torres
Alexandra Prados-Torres
TCTeresa Sanz Cuesta
Teresa Sanz Cuesta
BPBeatriz Poblador-Plou
Beatriz Poblador-Plou
MSMaria Sala
Maria Sala
Introduction Breast cancer has become a chronic disease due to survival improvement and the need to monitor the side effects of treatment and the disease itself. The aim of the SURBCAN study is to describe comorbidity, healthcare services use and adherence to preventive recommendations in long-term breast cancer survivors and to compare them with those in women without this diagnosis in order to improve and adapt the care response to this group of survivors. Methods and analysis Population-based retrospective cohort study using real-world data from cancer registries and linked electronic medical records in five Spanish regions. Long-term breast cancer survivors diagnosed between 2000 and 2006 will be identified and matched by age and administrative health area with women without this diagnosis. Sociodemographic and clinical variables including comorbidities and variables on the use of health services between 2012 and 2016 will be obtained from databases in primary and hospital care. Health services use will be assessed through the annual number of visits to primary care professionals and to specialists and through annual imaging and laboratory tests. Factors associated with healthcare utilisation and comorbidities will be analysed using multilevel logistic regression models. Recruitment started in December 2018. Ethics and dissemination This study was approved by the Ethics Committee of Parc de Salut Mar. The results of the study will be published in a peer-reviewed journal and will be presented at national and international scientific conferences and at patient associations. Trial registration number This protocol is registered in Clinical Trials.gov (identifier: NCT03846999).

19 April 2024 in Science Advances
Verified
Journal Article
Open access
LPLaia Peruchet-Noray
Laia Peruchet-Noray
ASAnja M. Sedlmeier
Anja M. Sedlmeier
NDNiki Dimou
Niki Dimou
HBHansjörg Baurecht
Hansjörg Baurecht
BFBéatrice Fervers
Béatrice Fervers
HFHeinz Freisling
Heinz Freisling
It remains unknown whether adiposity subtypes are differentially associated with colorectal cancer (CRC). To move beyond single-trait anthropometric indicators, we derived four multi-trait body shape phenotypes reflecting adiposity subtypes from principal components analysis on body mass index, height, weight, waist-to-hip ratio, and waist and hip circumference. A generally obese (PC1) and a tall, centrally obese (PC3) body shape were both positively associated with CRC risk in observational analyses in 329,828 UK Biobank participants (3728 cases). In genome-wide association studies in 460,198 UK Biobank participants, we identified 3414 genetic variants across four body shapes and Mendelian randomization analyses confirmed positive associations of PC1 and PC3 with CRC risk (52,775 cases/45,940 controls from GECCO/CORECT/CCFR). Brain tissue–specific genetic instruments, mapped to PC1 through enrichment analysis, were responsible for the relationship between PC1 and CRC, while the relationship between PC3 and CRC was predominantly driven by adipose tissue–specific genetic instruments. This study suggests distinct putative causal pathways between adiposity subtypes and CRC.

15 March 2024 in Cancer Communications
Verified
Journal Article
Open access
AJAnna Jansana
Anna Jansana
AAAviane Auguste
Aviane Auguste
MKMarina Kvaskoff
Marina Kvaskoff
AFAgnès Fournier
Agnès Fournier
EFEmma Fontvieille
Emma Fontvieille
HFHeinz Freisling
Heinz Freisling